Sage Journals: Discover world-class research

Abstract

Global clinical studies conducted in various countries and regions are increasing. Race and extrinsic ethnic factors are key covariates that may affect the pharmacokinetics (PK), efficacy, and safety of the drug. Genetic similarity among East Asian populations has been confirmed; thus, PK, efficacy, and safety in these populations are expected to be similar, but this has not been confirmed. This study presents a comparison of PK and safety among East Asians from clinical studies sponsored by Pfizer. Four compounds with different characteristics, including mechanism of actions and PK profiles, were selected, and retrospective PK and safety comparisons in East Asians were conducted. No distinct differences were observed in PK and safety across the 4 compounds. These results are consistent with previous reports on PK comparisons and meet the expectations based on genetic similarity among East Asians. Extrapolation of these findings to other compounds should be done with caution, but these results should support the consideration of mutual use of clinical data among East Asian countries.

Keywords

East Asia ethnic difference pharmacokinetics safety bazedoxifene crizotinib tolterodine varenicline

Get full access to this article

View all access options for this article.

References

International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299–1320.

Kurose

Sugiyama

Saito

. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9–54.

Myrand

Sekiguchi

Man

. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84:347–361.

Man

Farmen

Dumaual

. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50:929–940.

Tominaga

Ando

Nagai

. Balancing societal needs and regulatory certainty: the case study of peramivir in Japan. Clin Pharmacol Ther. 2013;93:342–344.

Kikkawa

Maruyama

Fujimoto

. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. J Clin Pharmacol. 2011;51:527–537.

Chandrasekaran

McKeand

Sullivan

. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos. 2009;37:1219–1225.

Shen

Ahmad

Park

. In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010;38:1471–1479.

Patat

McKeand

Baird-Bellaire

. Absolute/relative bioavailability of bazedoxifene acetate in healthy, postmenopausal women. Clin Pharmacol Ther. 2003;73:43.

10.

FDA review reports, clinical pharmacology biopharmaceutics review(s), application No. 202570s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000TOC.cfm. Published 2011. Accessed July 2013.

11.

Hills

Winter

Balfour

. Tolterodine. Drugs. 1998;55:813–820.

12.

Homma

Paick

Lee

. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92:741–747.

13.

Faessel

Obach

Rollema

. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010;49:799–816.

14.

Nakamura

Oshima

Fujimoto

. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;29:1040–1056.

15.

Fagerstrom

Nakamura

Cho

. Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries. Curr Med Res Opin. 2010;26:2165–2173.

16.

Tzvetkov

Vormfelde

Balen

. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86:299–306.

17.

Chen

Brown

. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009;19:497–504.

18.

Takane

Shikata

Otsubo

. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9:415–422.

19.

Ravva

Gastonguay

Tensfeldt

. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009;68:669–681.

20.

PMDA review report. http://www.info.pmda.go.jp/shinyaku/P200600014/40007900_21800AMY10088_Q102_1.pdf, http://www.info.pmda.go.jp/shinyaku/P200600014/40007900_21800AMY10088_Q104_1.pdf.

21.

Oishi

Chiba

Malhotra

. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. Drug Metab Pharmacokinet. 2011;26:236–241.

22.

Silverman

Christiansen

Genant

. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB